Conjugated estrogens

Estrogen — GENITO URINARY SYSTEM AND SEX HORMONES

Key facts

Conjugated estrogens is a drug in the Estrogen class catalogued in DrugCentral. It was first approved by the FDA in 1942. Its mechanism of action is classified as Estrogen Receptor Agonists. DrugCentral lists 2 molecular targets, including ESR1 and ESR2. Recorded indications include Dyspareunia and Menopausal flushing.

• Drug class: Estrogen.
• Mechanism of action: Estrogen Receptor Agonists.
• Molecular targets: ESR1 and ESR2 (2 listed in DrugCentral).
• Indications: Dyspareunia and Menopausal flushing.
• ATC code: G03CA57 (Natural and semisynthetic estrogens, plain).
• Molecular formula: C180H202Na10O40S10; molecular weight 3556.05 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Dyspareunia
• Menopausal flushing

Mechanism & targets

• Mechanism of action (MoA): Estrogen Receptor Agonists
• Established pharmacologic class: Estrogen

Molecular targets (2)

Target	Gene	Action	Activity
Estrogen receptor	ESR1	agonist	—
Estrogen receptor beta	ESR2	agonist	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1942-05-08	FDA	—	WYETH PHARMS INC

ATC classification

ATC code	Therapeutic hierarchy
G03CA57	GENITO URINARY SYSTEM AND SEX HORMONES › SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM › ESTROGENS › Natural and semisynthetic estrogens, plain
G03CC07	GENITO URINARY SYSTEM AND SEX HORMONES › SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM › ESTROGENS › Estrogens, combinations with other drugs

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Schizoaffective disorder	406.2
Breast cancer	380.5
Hot flush	360.3
Vulvovaginal burning sensation	326.4
Vulvovaginal discomfort	229.5
Cerebrovascular accident	224.8
Coronary artery disease	223.1
Depression	188.1
Maternal exposure during pregnancy	187.9
Pericarditis	171.8
Hyperlipidaemia	170.4
Death	168.4

Chemical structure

• Molecular formula: C₁₈₀H₂₀₂Na₁₀O₄₀S₁₀
• Molecular weight: 3556.05 g/mol
• CAS number: 12126-59-9
• InChIKey: —
• PubChem CID: 45357473

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Conjugated estrogens used for?

DrugCentral lists the following indications for Conjugated estrogens: Dyspareunia and Menopausal flushing.

How does Conjugated estrogens work?

Conjugated estrogens is classified as Estrogen Receptor Agonists; its molecular targets in DrugCentral include ESR1 (agonist) and ESR2 (agonist).

When was Conjugated estrogens first approved?

Conjugated estrogens was first approved by the FDA in 1942.

What drug class does Conjugated estrogens belong to?

Conjugated estrogens is in the Estrogen class.

What is the chemical formula of Conjugated estrogens?

Conjugated estrogens has the molecular formula C180H202Na10O40S10 and a molecular weight of 3556.05 g/mol.

Sources

• DrugCentral drug card 4855 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201649 — compound record and bioactivity
• PubChem CID 45357473 — chemical identifiers
• DrugBank DB00286 — drug record
• FDA UNII IU5QR144QX — substance identity
• DailyMed: FDA labels for Conjugated estrogens — current prescribing information (label search)
• UniProt P03372 (ESR1) — target protein
• UniProt Q92731 (ESR2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.